Novartis AG ADR (NVSy)

Currency in EUR
100.00
+0.60(+0.60%)
Delayed Data·
NVSy is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
99.80100.50
52 wk Range
87.80110.50
Key Statistics
Bid/Ask
100.00 / 101.00
Prev. Close
99.4
Open
99.8
Day's Range
99.8-100.5
52 wk Range
87.8-110.5
Volume
1.07K
Average Volume (3m)
547
1-Year Change
-1.01%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVSy Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Novartis AG ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Novartis AG ADR Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Compare NVSy to Peers and Sector

Metrics to compare
NVSy
Peers
Sector
Relationship
P/E Ratio
0.0x17.3x−0.5x
PEG Ratio
0.000.050.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x2.7x3.2x
Upside (Analyst Target)
0.0%30.3%42.7%
Fair Value Upside
Unlock13.7%5.8%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NVSy Income Statement

People Also Watch

49.09
BMY
+2.23%
70.31
NVO
+5.29%
72.95
AZN
+3.50%
476.37
TMO
+11.40%
504.94
MSFT
-0.07%

FAQ

What Stock Exchange Does Novartis AG ADR Trade On?

Novartis AG ADR is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Novartis AG ADR?

The stock symbol for Novartis AG ADR is "NVSy."

What Is the Novartis AG ADR Market Cap?

As of today, Novartis AG ADR market cap is 193.07B.

What Is Novartis AG ADR's Earnings Per Share (TTM)?

The Novartis AG ADR EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is NVSy a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Novartis AG ADR Stock Split?

Novartis AG ADR has split 0 times.

What is the current trading status of Novartis AG ADR (NVSy)?

As of 23 Jul 2025, Novartis AG ADR (NVSy) is trading at a price of 100.00, with a previous close of 99.40. The stock has fluctuated within a day range of 99.80 to 100.50, while its 52-week range spans from 87.80 to 110.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.